OCUL vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

OCUL

61.5
AI Score
VS
OCUL Wins

PCRX

35.0
AI Score

Investment Advisor Scores

OCUL

62score
Recommendation
BUY

PCRX

35score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric OCUL PCRX Winner
Revenue 24.26M 369.77M PCRX
Net Income -167.38M 7.57M PCRX
Net Margin -689.9% 2.0% PCRX
Operating Income -175.45M 11.17M PCRX
ROE -32.2% 1.1% PCRX
ROA -24.9% 0.6% PCRX
Total Assets 671.32M 1.24B PCRX
Cash 598.64M 205.88M OCUL
Current Ratio 13.11 5.04 OCUL
Free Cash Flow -141.29M 79.08M PCRX

Relative Price Performance (Last 90 Days)

OCUL 1M: -33.9% · 3M: -22.3% PCRX 1M: +47.5% · 3M: +40.4%

Current Technical Phase

OCUL

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.1%), weak momentum, RSI 33

RSI (14): 33.4 · Price: $6.61

PCRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (8.8% over 20 days), RSI 84

RSI (14): 83.6 · Price: $36.34

Fundamentals Snapshot

Metric OCUL PCRX
Market Cap — —
Forward P/E -4.5 10.5
Trailing P/E — 103.8
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin -3.4% 0.8%
Operating Margin -6.1% 0.1%
EPS -1.40 0.35
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, OCUL is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.